Shots:

• The P-III (True North) OLE study evaluates Zeposia (0.92mg) vs PBO in 823 patients with UC with an inadequate response or intolerant to conventional therapy or a biologic agent
• The results showed that the patients achieved clinical remission, clinical response, endoscopic improvement & corticosteroid-free remission was maintained @142wks. In an interim analysis @ 46/94/142wks., 45%/ 51%/45% were in clinical remission, 80%/84%/86% achieved clinical response, 64%/34%/14% patients completed a study
• Patients achieved clinical remission & clinical response @46 & 94wk., (70% & 69%) & (95% & 98%), no new safety signals with Zeposia use in 1158 patients in the pooled population

 Ref: Businesswire | Image: BMS